Fisch College of Pharmacy, The University of Texas at Tyler, TX, USA.
The University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
J Intensive Care Med. 2021 Jan;36(1):3-8. doi: 10.1177/0885066620957951. Epub 2020 Sep 10.
Coronavirus Disease 2019 (COVID-19) has had a devastating impact on the ability of highly trained healthcare providers to render sufficient care, due to both the significant demand on resources and the unique nature of this disease that make it resistant to traditional therapies. This review sought to determine the potential role of phosphodiesterase-5 inhibitors (PDE-5) in the management of COVID-19 by extrapolating relevant data and clinical studies from other related disease states, including acute respiratory distress syndrome, acute lung injury, and high altitude pulmonary edema. Following a literature search, 4 reports were analyzed and included in this review. While the heterogenicity of data and the small number of trials included limit the interpretation and applicability, it was consistently demonstrated that PDE-5 inhibitors lowered pulmonary arterial pressures. The overall benefit of these agents is seemingly dependent upon the etiology of the respiratory failure, which warrants expanded clinical investigation for COVID-19.
2019 年冠状病毒病（COVID-19）对高技能医疗保健提供者提供足够护理的能力造成了破坏性影响，这既是因为资源的巨大需求，也是因为这种疾病的独特性质，使其对传统疗法具有抵抗力。本综述旨在通过从其他相关疾病状态（包括急性呼吸窘迫综合征、急性肺损伤和高原肺水肿）中推断相关数据和临床研究，来确定磷酸二酯酶-5 抑制剂（PDE-5）在 COVID-19 管理中的潜在作用。经过文献检索，分析了 4 份报告并将其纳入本综述。虽然数据的异质性和试验数量少限制了其解释和适用性，但一致表明 PDE-5 抑制剂可降低肺动脉压。这些药物的整体益处似乎取决于呼吸衰竭的病因，这需要对 COVID-19 进行更广泛的临床研究。
